All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How could venetoclax combinations improve outcome in high-risk MDS?
During the EHA 2022 Congress, the MDS Hub was pleased to speak with Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How could venetoclax combinations improve outcome in high-risk MDS?
How could venetoclax combinations improve outcome in high-risk MDS?
Garcia begins by discussing current ongoing trials investigating venetoclax combinations, including the phase III VERONA study. Garcia goes on to talk about the use of venetoclax with HMA therapy for patients with relapsed/refractory disease, and the response and remission rates of different combinations.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox